Cost-effectiveness of vector control strategies for supplementing mass drug administration for eliminating lymphatic filariasis in India

Author:

Shepard Donald S.ORCID,Lwin Aung K.,Pulikkottil Sunish I.,Kalimuthu Mariapillai,Arunachalam Natarajan,Tyagi Brij K.,White Graham B.

Abstract

AbstractBackground/MethodologyDespite progress using mass drug administration (MDA), lymphatic filariasis (LF) remains a major public health issue in India. Vector control (VC) is hypothesized as a potentially useful addition to MDA towards LF elimination. We conducted cost-effectiveness analysis of MDA alone and augmented by VC single (VCS) or integrated VC approaches (VCI). Data came from historical controls and a 3-arm cluster randomized trial of 36 villages at risk of LF transmission in Tamil Nadu, India. The arms were: MDA alone (the standard of care); VCS (MDA plus expanded polystyrene beads for covering the water surface in wells and cesspits to suppress the filariasis vector mosquitoCulex quinquefasciatus), and VCI (VCS plus insecticidal pyrethroid impregnated curtains over windows, doors, and eaves). Economic costs in 2010 US$ combined government and community inputs from household to state levels. Outcomes were controlled microfilaria prevalence (MfP) and antigen prevalence (AgP) to conventional elimination targets (MfP<1% and AgP<2%) from 2010 to 2013, and disability adjusted life years (DALYs) averted.Principal FindingsThe estimated annual economic cost per resident was US$0.53 for MDA alone, US$1.02 for VCS, and US$1.83 for VCI. With MDA offered in all arms, all reduced LF prevalence substantially and significantly from 2010 to 2013. MDA proved highly cost effective at $112 per DALY, a very small (8%) share of India’s then per capita GDP. Progress towards elimination was comparable across all three study arms.ConclusionsThe well-functioning MDA was effective and very cost-effective for eliminating LF, leaving little scope for further improvement. Supplementary VC demonstrated no statistically significant additional benefit in this trial.Authors’ SummaryLymphatic filariasis (LF) is one of the twenty neglected tropical diseases (NTDs) that affect more than one billion people worldwide. As part of the effort toward global elimination of LF, the Indian State of Tamil Nadu government has implemented mass drug administration (MDA) repeatedly since 1996. Despite their efforts, LF had not yet been eliminated. Although vector control (VC) is proposed to augment regular MDA to help eliminate LF, little is known about the increased impact or costs. Our study compares the costs of MDA alone to the combination of MDA with alternative VC interventions. We calculated both program operating costs and costs to communities. We found MDA to be very cost-effective for eliminating LF. Against low levels of LF endemicity (≤10%), the study had limited ability to detect further improvements and found no significant incremental improvements from VC.

Publisher

Cold Spring Harbor Laboratory

Reference61 articles.

1. World Health Organization (WHO). Integrating neglected tropical diseases into global health and development: Fourth WHO report on neglected tropical diseases. Geneva: WHO; 2017. Available from: WHO/HTM/NTD/2017.01, 278pp.

2. Elimination of lymphatic filariasis in India: An update;J Ind Med Assoc,2015

3. The Neglected Tropical Diseases of India and South Asia: Review of Their Prevalence, Distribution, and Control or Elimination

4. Mass drug administration to eliminate lymphatic filariasis in India

5. Tyagi BK (Ed.). Lymphatic Filariasis Epidemiology, Treatment and Prevention - The Indian Perspective. Singapore: Springer Nature; 2018. xix+333pp. https://link.springer.com/book/10.1007/978-981-13-391-2 p.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3